Sanofi (SNYNF,SNY) announced Monday that it has agreed to acquire Blueprint Medicines Corp. (BPMC) in a transaction valued at about $9.5 billion on a fully diluted basis, including potential contingent value right payments.
The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the European Union, and a promising advanced and early-stage immunology pipeline. Furthermore, Blueprints established presence among allergists, dermatologists, and immunologists is expected to enhance Sanofis growing immunology pipeline.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.